Company Encyclopedia
View More
name
Nyxoah SA
NYXH.US
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
1.391 T
NYXH.USMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking122/172
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-107.57%E
    • Profit Margin-1484.68%E
    • Gross Margin60.50%A
  • Growth ScoreC
    • Revenue YoY13.44%B
    • Net Profit YoY-61.55%D
    • Total Assets YoY-31.14%E
    • Net Assets YoY-48.89%E
  • Cash ScoreC
    • Cash Flow Margin-6.74%D
    • OCF YoY13.44%B
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreC
    • Gearing Ratio45.56%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nyxoah Launches Genio Sleep Apnea Therapy in the Netherlands

    Nyxoah SA has launched its Genio® system for Obstructive Sleep Apnea in the Netherlands, marking a significant step in its European expansion. The Genio system offers a patient-centric alternative to CPAP therapy, featuring bilateral neurostimulation, no implanted battery, and MRI compatibility. The first implants were successfully performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen.

    Reuters·
    US
    NYXH
    +4.30%
    Reuters·
    US
    NYXH
    +4.30%

    Nyxoah Launches Genio Therapy Commercially in the Netherlands

    Nyxoah SA has launched its Genio® system commercially in the Netherlands, expanding its European presence. The Genio system, a battery-free neurostimulation therapy for obstructive sleep apnea, offers features like bilateral nerve stimulation and MRI compatibility. This launch marks a significant step in Nyxoah's international rollout, providing Dutch patients with an alternative to CPAP. The first implants were successfully performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen.

    Reuters·
    US
    NYXH
    +4.30%
    Reuters·
    US
    NYXH
    +4.30%

    Nyxoah SA to Join Piper Sandler 37th Annual Healthcare Conference

    Nyxoah SA will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 1:30 p.m. ET. The event will be available via live audio webcast on Nyxoah’s investor relations page.

    Reuters·
    US
    NYXH
    +4.30%
    Reuters·
    US
    NYXH
    +4.30%

    Nyxoah Gets Increased Reimbursement Framework for Genio Therapy Under New CMS Rule

    Nyxoah SA announced that the US Centers for Medicare & Medicaid Services has approved a new rule increasing reimbursement rates for its Genio neurostimulation therapy for obstructive sleep apnea. Effective January 1, 2026, hospital outpatient department reimbursement will rise 48% to $45,000, and ambulatory surgery centers facility reimbursement will increase 58% to $42,373.

    fidelity·
    US
    NYXH
    +4.30%
    fidelity·
    US
    NYXH
    +4.30%

    Nyxoah SA Announces Updated Total Issued Shares and Voting Rights

    Nyxoah SA announced that its total issued shares and voting rights are 43,026,460 ordinary shares. The company also reported 3,258,819 rights to subscribe to securities with voting rights granted but not issued, and 692,677 subscription rights issued but not granted.

    Reuters·
    US
    NYXH
    +4.30%
    Reuters·
    US
    NYXH
    +4.30%
    © 2025 Longbridge｜Disclaimer